基因C677T多态性在2型糖尿病合并大血管病变中的意义

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1027 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the possible association between MTHFR gene C677T mutation and type 2 diabetes mellitus (T2DM) combined with macrovascular complications. Methods Clinical data of 380 T2DM patients (218 simple T2DM and 162 T2DM patients with macrovascular complications) and 306 healthy controls were selected from the First Hospital of Harbin from October 2015 to January 2017. Blood genomic DNA was separated and the polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) assay was used for genotyping of the MTHFR gene C677T mutation. Results The frequencies of TT genotypes and T alleles of the C677T mutation in MTHFR gene in T2DM patients with macrovascular complications were statistically significantly higher than those of simple T2DM patients (P < 0.01). The homocysteine level in genotypic TT patients was significantly higher than that of genotype CT and CC patients (P ＜ 0.05, P ＜ 0.01). Conclusion The combination of T2DM with macroangiopathy may be related with the mutation of the MTHFR gene C677T.

Key words： Diabetic mellitus Macrovascular complications Methylenetetrahydrofolate reductase C677T mutation Genotype Homocysteine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Jinhui1 WANG Feifei1 LI Weimin2▲

Cite this article:

WANG Jinhui1 WANG Feifei1 LI Weimin2▲. The significance of C677T mutation in type 2 diabetes mellitus combined with macrovascular complications[J]. 中国医药导报, 2018, 15(14): 102-106.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I14/102

[1] Da RF，Ogurtsova K，Linnenkamp U，et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes [J]. Diabetes Res Clin Pract，2016，117：48-54.
[2] Boulton AJ，Vinik AI，Arezzo JC，et al. Diabetic neuropathies：a statement by the American Diabetes Association [J]. Diabetes Care，2005，28（4）：956-962.
[3] Barrett AM，Lucero MA，Le T，et al. Epidemiology，public health burden，and treatment of diabetic peripheral neuropathic pain：a review [J]. Pain Med，2007，8 Suppl 2：S50-S62.
[4] Huang D，Refaat M，Mohammedi K，et al. Macrovascular Complications in Patients with Diabetes and Prediabetes [J]. Biomed Res Int，2017，2017（9）：7839101. doi: 10.1155/2017/7839101
[5] American Diabetes A. Economic costs of diabetes in the U.S. In 2007 [J]. Diabetes Care，2008，31（3）：596-615.
[6] Van DS，Beulens JW，Van YT，et al. The global burden of diabetes and its complications：an emerging pandemic [J]. Eur J Cardiovasc Prev Rehabil，2010，17 Suppl 1：S3-S8.
[7] Bosch-Marcé M，Pola R，Wecker AB，et al. Hyperhomocyst（e）inemia impairs angiogenesis in a murine model of limb ischemia [J]. Vasc Med，2005，10（1）：15-22.
[8] Majumder M，Mollah FH，Hoque M，et al. Serum Homocysteine and its Association with Glycemic Control in Type 2 Diabetic Patients [J]. Mymensingh Med J，2017，26（4）：921-926.
[9] Sahu A，Gupta T，Kavishwar A，et al. Cardiovascular disease among patients with type 2 diabetes：Role of Homocysteine as an inflammatory marker [J]. Ukr Biochem J，2016，88（2）：35-44.
[10] Li MN，Wang HJ，Zhang NR，et al. MTHFR C677T gene polymorphism and the severity of coronary lesions in acute coronary syndrome [J]. Medicine（Baltimore），2017， 96（49）：e9044.
[11] Fox CS，Coady S，Sorlie PD，et al. Trends in cardiovas-cular complications of diabetes [J]. JAMA，2004，292：2495-2499.
[12] Pollex RL，Mamakeesick M，Zinman B，et al. Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes [J]. Cardiovasc Diabetol，2005，4：17.
[13] Fekih-Mrissa N，Mrad M，Ibrahim H，et al. Methylenetetrahydrofolate Reductase（MTHFR）（C677T and A12 98C） Polymorphisms and Vascular Complications in Patients with Type 2 Diabetes [J]. Can J Diabetes，2017，41（4）：366-371.
[14] Kaye JM，Stanton KG，McCann VJ，Homocysteine，folate，methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects [J]. Clin Sci（Lond），2002，102（6）：631-637.
[15] Zhu B，Wu X，Zhi X，et al. Methylenetetrahydrofolate reductase C677T polymorphism and type 2 diabetes mellitus in Chinese population：a meta-analysis of 29 case-control studies [J]. PLoS One，2014，9（7）：e102443.
[16] Miguel-Yanes JM，Jiménez-García R，Hernández-Barrera V，et al. Impact of type 2 diabetes mellitus on in-hospital-mortality after major cardiovascular events in Spain（2002-2014）[J]. Cardiovasc Diabetol，2017，16（1）：126.
[17] Karlova O，Grinzovskyy A，Kuzminska O，et al. Hyperhomocysteinemia as a predictor of cardiovascular diseases in lead-exposed subjects [J]. Georgian Med News，2017（271）：86-90.
[18] Ma Y，Li L，Geng XB，et al. Correlation Between Hyperhomocysteinemia and outcomes of patients with acute myocardial infarction [J]. Am J Ther，2016，23（6）：e1464-e1468.
[19] Yan G，Wang D，Qiao Y，et al. Relationship between hyperhomocysteine and long-term outcome of coronary artery disease patients after drug-eluting stent implantation [J]. Zhonghua Xin Xue Guan Bing Za Zhi，2015，43（11）：943-947.
[20] Brattstrom L，Wilcken DE，Homocysteine and cardiovascular disease：cause or effect ? [J]. Am J Clin Nutr，2000， 72（2）：315-323.
[21] Benrahma H，Abidi O，Melouk L，et al.Association of the C677T polymorphism in the human methylenetetrahydrofolate reductase（MTHFR）gene with the genetic predisposition for type 2 diabetes mellitus in a Moroccan population [J]. Genet Test Mol Biomarkers，2012，16（5）：383-387.
[22] Ramkaran P，Phulukdaree A，Khan S，et al. Methylenetetrahydrofolate reductase C677T polymorphism is associated with increased risk of coronary artery disease in young South African Indians [J]. Gene，2015，571（1）：28-32.
[23] Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function [J]. Curr Drug Metab，2005，6（1）：27-36.
[24] Lotfiazar A，Einollahi B. The role of supplements in reducing cardiovascular events by decrease in highly sensitive C-reactive protein and serum homocysteine [J]. Saudi J Kidney Dis Transpl，2017，28（6）：1451-1452.
[25] Jakubowski H. Pathophysiological consequences of homocysteine excess[J]. J Nutr，2006，136（6 Supp l）：1741S-1749S.
[26] Kerkeni M，Tnani M，Chuniaud L，et al. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells：evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone [J]. Mol Cell Biochem，2006，291（1/2）：119-126.